Clinical Performance Evaluation of IVDs in India: Regulatory Requirements

This article provides an overview of the regulatory framework governing Clinical Performance Evaluation (CPE) of In-Vitro Diagnostic devices (IVDs) in India. It outlines the classification of IVDs, roles of regulatory authorities, approval pathways, and key study design considerations under the Medical Device Rules, 2017, offering practical insights for manufacturers, researchers, and regulatory professionals.

Introduction

In-Vitro Diagnostic (IVD) devices include reagents, kits, instruments, and systems intended for the examination of human specimens such as blood, urine, or tissue outside the human body. They fulfil a vital role in healthcare by generating reliable information to support clinical decision-making, disease diagnosis, screening, monitoring, and prognosis. Additionally, they help in assessing disease predisposition and compatibility for blood transfusion or organ

In India, all IVD kits and reagents are regulated as medical devices under the Medical Device Rules (MDR), 2017.2 These regulations require evidence of safety, analytical performance, and clinical performance prior to market authorisation. In vitro diagnostic Clinical Performance Evaluation (CPE) is therefore a critical regulatory requirement, ensuring that IVDs perform as intended in the target population and clinical setting.3 This article highlights the regulatory framework governing clinical performance evaluation of IVD (India) and key considerations for study design for IVD clinical trial (India).

Regulatory Framework for IVD Clinical Trial in India

The regulatory framework in India ensures that only IVDs meeting defined safety and performance requirements are approved for import, manufacture, and marketing.

The Central Drugs Standard Control Organization (CDSCO) acts as the national regulatory authority responsible for the licensing, oversight, and post-market surveillance of IVDs.
Within CDSCO, the Medical Devices & Diagnostics Division is specifically responsible for the scientific and regulatory review of IVD kits and reagents.
The CDSCO IVD guidelines must be diligently adhered to for timely approvals of IVDs.

IVD Classification and Risk-Based Regulatory Approach

IVD regulatory requirements (India) classify medical devices into Classes A, B, C, and D based on their intended use and the potential risk to patients and public health. This classification determines the level of regulatory oversight and clinical evidence required.

Class A (Low risk): Specimen receptacles and simple routine chemistry devices.
Class B (Low to moderate risk): Devices such as pregnancy test kits and urine strips.
Class C (Moderate to high risk): Devices including genetic testing and PSA kits.
Class D (High risk): Critical diagnostics such as blood grouping and hepatitis B kits.

Regulatory Authorities and Their Jurisdiction

The Central Licensing Authority (CLA) is the competent authority for:

Import of all classes of IVD medical devices.
Manufacture of Class C and Class D IVDs.
Approval and oversight of clinical performance evaluation of new IVDs.
Coordination with State Licensing Authorities (SLAs).

The SLA, headed by the State Drugs Controller, is responsible for:

Manufacture for sale or distribution of Class A and Class B IVDs.
Regulation of the sale, stock, exhibition, and distribution of IVDs across all classes within the state.

IVD Clinical Performance Study (India)

Regulatory Requirements

CPE of any new IVD Medical Device in India requires prior permission from the CLA. No sponsor may conduct CPE using human specimens unless such permission is granted and the evaluation is conducted in accordance with the approved regulatory framework.

Key regulatory requirements for the grant of permission include:

Submission of an application in Form MD-24 to the CLA.
Payment of the prescribed fee (as per the Second Schedule), where applicable.
Submission of supporting documentation as specified in the Seventh Schedule.

Upon review, the CLA may:

Grant permission in Form MD-25, or
Reject the application within 90 days, with reasons recorded in writing.
Abbreviate, defer, or waive CPE requirements in the public interest.

The CPE application dossier must include:

Approval from a registered Ethics Committee.
Details of the sample source and quantity.
Device description, intended use, labelling, and regulatory status in other countries.
In-house performance data (sensitivity, specificity, stability, repeatability, reproducibility).
A clinical performance evaluation plan, case report forms, and the investigator undertakings.
List of participating laboratories or institutions.
A performance evaluation report from a laboratory designated under Rule 19.

The key CDSCO application and approval forms relevant to clinical performance evaluation of IVDs in India are summarised in Table

Regulatory Activity	Application Form	Approval/Licence Form
Manufacture of IVDs for evaluation and CPE (non-commercial)	MD-12	MD-13
Import of IVDs for evaluation and CPE (non-commercial)	MD-16	MD-17
Conduct of clinical performance evaluation of a new IVD	MD-24	MD-25
Import or manufacture of a new IVD for commercial sale	MD-28	MD-29
Registration of IVD testing laboratories	MD-39	MD-40

Study Design

Study design for clinical performance evaluation should be scientifically justified and aligned with the intended use of the device. The following elements are important when planning a CPE study:

Clearly Defined Objectives and Intended Use

Definition of the clinical question and primary performance parameters (e.g., sensitivity, specificity, agreement with a reference method) in relation to the intended use and target population.

Study Design and Methodology

Selection of an appropriate study design based on clinical context and data availability.
Establishment of inclusion and exclusion criteria reflective of the intended use population.

Comparator or Reference Method

Identification and justification of an appropriate comparator or reference standard that is clinically relevant and scientifically validated.

Sample Size and Specimen Selection

Statistical justification of sample size to adequately evaluate performance endpoints.>
Inclusion of representative specimens reflecting clinical variability and intended use settings.

Performance Endpoints and Statistical Analysis

Predefinition of performance endpoints such as sensitivity, specificity, predictive values, agreement, and reproducibility.
Development of a statistical analysis plan detailing analytical methods and confidence interval estimation.

Quality Assurance and Bias Control

Implementation of procedures to minimize bias and ensure data integrity across study sites or laboratories.
Documentation of personnel training, instrument calibration, and quality control measures.

Documentation and Record Keeping

Maintenance of complete records related to study conduct, raw data, deviations, and analysis outputs for regulatory inspection.
Ensuring traceability of specimens, test results, and evaluator decisions.

Conclusion

CMeeting the CDSCO IVD clinical evaluation is a key regulatory requirement for their approval in India post IVD clinical performance study (India). A clear understanding of MDR 2017 requirements, coupled with robust well-designed clinical performance study design for IVD, is essential to demonstrate device safety and performance in IVD clinical trials in India . Additionally, adherence to regulatory expectations and study design practices facilitates timely regulatory approval and ensures reliable diagnostic outcomes in clinical practice.

Short Summary

In-Vitro Diagnostic (IVD) devices are regulated medical devices in India under the Medical Device Rules (MDR), 2017.
Clinical Performance Evaluation (CPE) is a mandatory regulatory requirement to demonstrate that IVDs perform in terms of diagnostic sensitivity, specificity, & usability as intended in the target population.
The Central Drugs Standard Control Organization (CDSCO) oversees the regulation of IVDs, with responsibilities divided between the Central Licensing Authority (CLA) and State Licensing Authorities (SLAs) based on device risk class.
CPE of new IVDs requires prior approval from the CLA and must comply with Good Clinical Practice, Ethics Committee approval, and registration with the Clinical Trials Registry of India.